Avadel Pharmaceuticals Investor Relations Material
Latest events
Q1 2025
Avadel Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Avadel Pharmaceuticals plc
Access all reports
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing innovative treatments for chronic conditions, particularly in the central nervous system (CNS) field. The company's flagship product, LUMRYZ™, is an extended-release formulation of sodium oxybate used to treat cataplexy and excessive daytime sleepiness in adults with narcolepsy. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Key slides for Avadel Pharmaceuticals plc
Q1 2025
Avadel Pharmaceuticals plc
Q1 2025
Avadel Pharmaceuticals plc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AVDL
Country
🇺🇸 United States